Tag Archives: Onconova Therapeutics

The CFO of Onconova Therapeutics (NASDAQ: ONTX) is Buying Shares

Yesterday, the CFO of Onconova Therapeutics (ONTX – Research Report), Mark Patrick Guerin, bought shares of ONTX for $5,555. This recent transaction increases Mark Patrick Guerin’s holding in the company by 20.5% to a total of $33.86K. In addition to

Maxim Group Keeps Their Hold Rating on Onconova Therapeutics (ONTX)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Onconova Therapeutics (ONTX – Research Report). The company’s shares closed last Friday at $0.26, close to its 52-week low of $0.10. According to TipRanks.com, McCarthy

A Director at Onconova Therapeutics (NASDAQ: ONTX) is Selling Shares

Yesterday, a Director at Onconova Therapeutics (ONTX – Research Report), Premkumar Reddy, sold shares of ONTX for $142.5K. This is Reddy’s first Sell trade following 7 Buy transactions. In addition to Premkumar Reddy, one other ONTX executive reported Sell trades

Analysts Have Conflicting Sentiments on These Healthcare Companies: Onconova Therapeutics (NASDAQ: ONTX), Immunomedics (NASDAQ: IMMU) and Envista Holdings (NYSE: NVST)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Onconova Therapeutics (ONTX – Research Report), Immunomedics (IMMU – Research Report) and Envista Holdings (NVST – Research Report). Onconova Therapeutics (ONTX) In a report issued

Onconova Therapeutics (ONTX) Gets a Buy Rating from H.C. Wainwright

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Onconova Therapeutics (ONTX – Research Report), with a price target of $2.00. The company’s shares closed last Wednesday at $1.28. According to TipRanks.com, Pantginis is

The President of Onconova Therapeutics (NASDAQ: ONTX) is Buying Shares

Today, the President of Onconova Therapeutics (ONTX – Research Report), Steven Fruchtman, bought shares of ONTX for $9,648. This recent transaction increases Steven Fruchtman’s holding in the company by 17.94% to a total of $63.62K. In addition to Steven Fruchtman,